Published in Pharm Res on September 12, 2016
Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol (2005) 5.13
PEGylation, successful approach to drug delivery. Drug Discov Today (2005) 4.56
Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science (2002) 3.98
Postsynaptic density 95 controls AMPA receptor incorporation during long-term potentiation and experience-driven synaptic plasticity. J Neurosci (2004) 3.30
Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch (2010) 2.83
Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem (1977) 2.65
Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology (2000) 2.26
Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet (2001) 2.23
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci (2008) 2.21
Peptide and protein PEGylation: a review of problems and solutions. Biomaterials (2001) 2.00
Pharmacologic mechanisms of crystal meth. CMAJ (2008) 1.60
Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol (2005) 1.49
Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol (2003) 1.49
Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos (2003) 1.49
Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol (2006) 1.39
High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci (2004) 1.33
Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol (2002) 1.30
Methamphetamine abuse. Am Fam Physician (2007) 1.28
PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem (2006) 1.26
The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des (2004) 1.25
Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets (2011) 1.21
Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J Pharmacol Exp Ther (2008) 1.20
Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology (Berl) (2006) 1.17
Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol (2003) 1.13
Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci (2004) 1.12
Synthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines. J Med Chem (2011) 1.10
Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse. AAPS J (2006) 1.03
Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res (2010) 1.02
Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther (2000) 1.02
Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res (1990) 1.00
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog (2005) 0.98
Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs (2013) 0.97
Methamphetamine induces alterations on hippocampal NMDA and AMPA receptor subunit levels and impairs spatial working memory. Neuroscience (2007) 0.94
Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem Int (2005) 0.94
Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering. Sci Rep (2014) 0.94
Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet (2004) 0.92
Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal Biochem (1997) 0.91
Neurotoxic effects of methamphetamine. Neurochem Res (2009) 0.91
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J Control Release (2009) 0.88
Motor impairments, striatal degeneration, and altered dopamine-glutamate interplay in mice lacking PSD-95. J Neurogenet (2014) 0.87
Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology (2013) 0.87
Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine. Synapse (1996) 0.86
Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug Chem (2005) 0.85
Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization. Bioconjug Chem (2012) 0.85
A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. Sci Rep (2015) 0.85
Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla. Eur J Pharmacol (1971) 0.82
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor. BioDrugs (2015) 0.82
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development. Toxicol Pathol (2015) 0.80
Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b. J Interferon Cytokine Res (2013) 0.79